917600-22-7

Upstream product

• 917600-21-6 (3R,4R)-3-((S)-4-biphenyl-3-yl-(3-t-butyldimethylsilyloxy)-1-butyn-1-yl)-(4-t-butyldimethylsilyloxy)-2-methylenecyclopentanone 
• 131392-87-5 (4E)-5-carbomethoxypent-4-enylzinc(II) iodide 
• 71912-70-4 ethyl 2-((1,1'-biphenyl)-3-yl)acetate 
• 14062-30-7 ethyl 2-(3-bromophenyl)acetate 
• 917600-18-1 (S)-2-acetyloxy-1-(3-biphenyl)-3-butyne 
• 917600-19-2 (R)-1-(3-biphenyl)-3-butyn-2-ol 
• 917600-17-0 (S)-1-(3-biphenyl)-3-butyn-2-ol 
• 917600-16-9 1-(3-biphenyl)-3-butyn-2-ol 

Relevant academic research and scientific papers

PROSTAGLANDIN DERIVATIVE

A prostaglandin derivative represented by the formula: (I) wherein R1 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an alkenyl group having 2 to 4 carbon atoms; X represents an ethylene group, a trimethylene group, a vinylene group, an ethynylene group or a group represented by the formula: -SCH2-; R2 and R3 independently represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an alkyl group having 1 to 6 carbon atoms which is substituted by an alkoxy group having 1 to 6 carbon atoms, a phenyl group, a substituted phenyl group, a furyl group or a thienyl group, or a pharmaceutically acceptable salt thereof or a hydrate of the derivative or salt. These compounds show a satisfactory level of anti-inflammatory effect while minimizing the cAMP production-enhancing effect and is provided for reducing the adverse side effects that may be caused by an EP4 agonist.